Key Takeaways:
- CSPC Pharma's 1Q26 net profit fell 40.3% YoY to RMB842 million
- The stock tumbled 7.8% to HKD6.86 on turnover of HKD462 million
- Short selling accounted for 21.3% of trading volume during the session
Back
CSPC Pharma drops 7.8% as first-quarter profit slides 40%
CSPC Pharmaceutical Group Ltd. reported a 40.3% drop in first-quarter net profit to RMB842 million, sending its Hong Kong-listed shares to a session low of HKD6.86.
"The profit decline reflects ongoing pricing pressure in China's generic drug market and increased investment in innovative drug R&D, including AI-driven drug discovery," a UBS analyst said in a note. The bank upgraded CSPC Pharma to Buy, arguing the stock's valuation does not yet reflect the company's AI drug research capabilities.
The stock closed at HKD7.26 at midday, down 2.4%, before extending losses after the earnings announcement. It last traded at HKD6.86, down 7.8%, with 64.4 million shares changing hands worth HKD462 million. Short selling accounted for 21.3% of trading volume, or HKD50.6 million, data from the Hong Kong exchange show.
The 40% profit decline marks one of the steepest quarterly drops for the drugmaker in recent years, underscoring the margin pressure facing China's generic pharmaceutical sector amid government procurement programs that have driven down drug prices. CSPC Pharma did not disclose revenue or earnings per share figures in its brief filing, nor did it provide forward guidance.
The selloff pushed CSPC Pharma's market capitalization below HKD85 billion, erasing roughly HKD7 billion in value in a single session. The stock has now fallen about 18% year to date, underperforming the Hang Seng Index's 12% gain over the same period. Investors will watch for any segment-level breakdown or margin commentary when the company holds its earnings briefing, as well as updates on its pipeline of innovative drugs and AI research initiatives.
This article is for informational purposes only and does not constitute investment advice.
